Risk assessment and adjuvant systemic therapy in resected stage II colon cancer

Veena Shankaran, Polina Khrizman, Al B. Benson

Research output: Contribution to journalReview article

Abstract

Adjuvant chemotherapy following surgical resection of stage III colon cancer has become the standard of care based on numerous large randomized trials that have demonstrated benefit in overall survival. For patients with stage II colon cancer, the picture is more uncertain. Although clinical trials have not reported a significant survival benefit for adjuvant chemotherapy in stage II disease, patients with certain high-risk clinical and pathologic features may warrant postoperative treatment. Molecular markers, such as 18q loss of heterozygosity and mi crosatellite instability, may also help to prognosticate patients with stage II colon cancer, although data supporting their role have been largely retrospective. The role of these markers in stage II disease is being prospectively investigated. Continued enrollment in clinical trials and further risk stratification will help clarify the optimal management of patients with stage II colon cancer.

Original languageEnglish (US)
Pages (from-to)158-165
Number of pages8
JournalCurrent Colorectal Cancer Reports
Volume5
Issue number3
DOIs
StatePublished - Jul 1 2009

Fingerprint

Colonic Neoplasms
Adjuvant Chemotherapy
Clinical Trials
Survival
Loss of Heterozygosity
Therapeutics
Standard of Care

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology

Cite this

@article{097d30ef17fb4e5187167dba3ef58abd,
title = "Risk assessment and adjuvant systemic therapy in resected stage II colon cancer",
abstract = "Adjuvant chemotherapy following surgical resection of stage III colon cancer has become the standard of care based on numerous large randomized trials that have demonstrated benefit in overall survival. For patients with stage II colon cancer, the picture is more uncertain. Although clinical trials have not reported a significant survival benefit for adjuvant chemotherapy in stage II disease, patients with certain high-risk clinical and pathologic features may warrant postoperative treatment. Molecular markers, such as 18q loss of heterozygosity and mi crosatellite instability, may also help to prognosticate patients with stage II colon cancer, although data supporting their role have been largely retrospective. The role of these markers in stage II disease is being prospectively investigated. Continued enrollment in clinical trials and further risk stratification will help clarify the optimal management of patients with stage II colon cancer.",
author = "Veena Shankaran and Polina Khrizman and Benson, {Al B.}",
year = "2009",
month = "7",
day = "1",
doi = "10.1007/s11888-009-0023-8",
language = "English (US)",
volume = "5",
pages = "158--165",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "3",

}

Risk assessment and adjuvant systemic therapy in resected stage II colon cancer. / Shankaran, Veena; Khrizman, Polina; Benson, Al B.

In: Current Colorectal Cancer Reports, Vol. 5, No. 3, 01.07.2009, p. 158-165.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Risk assessment and adjuvant systemic therapy in resected stage II colon cancer

AU - Shankaran, Veena

AU - Khrizman, Polina

AU - Benson, Al B.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Adjuvant chemotherapy following surgical resection of stage III colon cancer has become the standard of care based on numerous large randomized trials that have demonstrated benefit in overall survival. For patients with stage II colon cancer, the picture is more uncertain. Although clinical trials have not reported a significant survival benefit for adjuvant chemotherapy in stage II disease, patients with certain high-risk clinical and pathologic features may warrant postoperative treatment. Molecular markers, such as 18q loss of heterozygosity and mi crosatellite instability, may also help to prognosticate patients with stage II colon cancer, although data supporting their role have been largely retrospective. The role of these markers in stage II disease is being prospectively investigated. Continued enrollment in clinical trials and further risk stratification will help clarify the optimal management of patients with stage II colon cancer.

AB - Adjuvant chemotherapy following surgical resection of stage III colon cancer has become the standard of care based on numerous large randomized trials that have demonstrated benefit in overall survival. For patients with stage II colon cancer, the picture is more uncertain. Although clinical trials have not reported a significant survival benefit for adjuvant chemotherapy in stage II disease, patients with certain high-risk clinical and pathologic features may warrant postoperative treatment. Molecular markers, such as 18q loss of heterozygosity and mi crosatellite instability, may also help to prognosticate patients with stage II colon cancer, although data supporting their role have been largely retrospective. The role of these markers in stage II disease is being prospectively investigated. Continued enrollment in clinical trials and further risk stratification will help clarify the optimal management of patients with stage II colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=79952654327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952654327&partnerID=8YFLogxK

U2 - 10.1007/s11888-009-0023-8

DO - 10.1007/s11888-009-0023-8

M3 - Review article

AN - SCOPUS:79952654327

VL - 5

SP - 158

EP - 165

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 3

ER -